SynthesisStem cells translational medicine2019
Concise Review: Patency of Small-Diameter Tissue-Engineered Vascular Grafts: A Meta-Analysis of Preclinical Trials.
Synthesis in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Resolving differential vascular graft remodeling using longitudinal multiphoton tracking in a 3D culture platform.Materials today. Bio · 2026Article
- Ex vivo endothelialized cECM-enriched core-shell fibrous vascular graft promotes rapid regenerative remodeling in vivo.Bioactive materials · 2026Article
- Rolled amniotic membrane for practical vascular graft development: a scoping review.Human cell · 2026Article
- Decellularized vascular matrix material-based TEVG coated with PRP for anti-degradation and anti-inflammation.International journal of surgery (London, England) · 2026Article
- Preparation and in vivo effectiveness evaluation of heparin-loaded PLGA@PCL core-shell fiber small-diameter vascular grafts.PloS one · 2026Article
- Barriers to clinical translation of small-diameter tissue-engineered vascular grafts in peripheral reconstruction.JVS-vascular science · 2026Review
- Immunomodulation and Mechanical Characterization of Manuka Honey-Incorporated Near-Field Electrospun Bioresorbable Vascular Grafts.Bioengineering (Basel, Switzerland) · 2025Article
- Six-Month Patency of Long Carotid Bypass Grafts Constructed with In-Body Tissue Architecture-Induced Small-Diameter Biotubes in a Goat Model.Bioengineering (Basel, Switzerland) · 2025Article
- Surface Modification of PEEKs with Cyclic Peptides to Support Endothelialization and Antithrombogenicity.Materials today. Communications · 2024Article
- Carotid Artery Bypass Surgery of In-Body Tissue Architecture-Induced Small-Diameter Biotube in a Goat Model: A Pilot Study.Bioengineering (Basel, Switzerland) · 2024Article
- Vascular tissue reconstruction by monocyte subpopulations on small-diameter acellular grafts via integrin activation.Materials today. Bio · 2023Article
- Biological Materials for Tissue-Engineered Vascular Grafts: Overview of Recent Advancements.Biomolecules · 2023Review
- A bioactive compliant vascular graft modulates macrophage polarization and maintains patency with robust vascular remodeling.Bioactive materials · 2023Article
- Article
- Vascular Grafts: Technology Success/Technology Failure.BME frontiers · 2023Review
- Review
- Scaffold Engineering with Flavone-Modified Biomimetic Architecture for Vascular Tissue Engineering Applications.Tissue engineering and regenerative medicine · 2022Article
- Virtual Reality Cardiac Surgical Planning Software (CorFix) for Designing Patient-Specific Vascular Grafts: Development and Pilot Usability Study.JMIR cardio · 2022Article
- Heparin Immobilization of Tissue Engineered Xenogeneic Small Diameter Arterial Scaffold Improve Endothelialization.Tissue engineering and regenerative medicine · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several patient groups undergoing small-diameter (<6 mm) vessel bypass surgery have limited autologous vessels for use as grafts. Tissue-engineered vascular grafts (TEVG) have been suggested as an alternative, but the ideal TEVG remains to be generated, and a systematic overview and meta-analysis of clinically relevant studies is lacking. We systematically searched PubMed and Embase databases for (pre)clinical trials and identified three clinical and 68 preclinical trials ([>rabbit]; 873 TEVGs) meeting the inclusion criteria. Preclinical trials represented low to medium risk of bias, and binary logistic regression revealed that patency was significantly affected by recellularization, TEVG length, TEVG diameter, surface modification, and preconditioning. In contrast, scaffold types were less important. The patency was 63.5%, 89%, and 100% for TEVGs with a median diameter of 3 mm, 4 mm, and 5 mm, respectively. In the group of recellularized TEVGs, patency was not improved by using smooth muscle cells in addition to endothelial cells nor affected by the endothelial origin, but seems to benefit from a long-term (46-240 hours) recellularization time. Finally, data showed that median TEVG length (5 cm) and median follow-up (56 days) used in preclinical settings are relatively inadequate for direct clinical translation. In conclusion, our data imply that future studies should consider a TEVG design that at least includes endothelial recellularization and bioreactor preconditioning, and we suggest that more standard guidelines for testing and reporting TEVGs in large animals should be considered to enable interstudy comparisons and favor a robust and reproducible outcome as well as clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.